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Abstract
Background: Elevated levels of factor VIII (FVIII) and von Willebrand Factor (vWF) are well-established risk factors
for cardiovascular diseases, in particular venous thrombosis. Although high, the heritability of these traits is poorly
explained by the genetic factors known so far. The aim of this work was to identify novel single nucleotide
polymorphisms (SNPs) that could influence the variability of these traits.
Methods: Three independent genome-wide association studies for vWF plasma levels and FVIII activity were
conducted and their results were combined into a meta-analysis totalling 1,624 subjects.
Results: No single nucleotide polymorphism (SNP) reached the study-wide significance level of 1.12 × 10
-7 that
corresponds to the Bonferroni correction for the number of tested SNPs. Nevertheless, the recently discovered
association of STXBP5, STX2, TC2N and CLEC4M genes with vWF levels and that of SCARA5 and STAB2 genes with
FVIII levels were confirmed in this meta-analysis. Besides, among the fifteen novel SNPs showing promising
association at p < 10
-5 with either vWF or FVIII levels in the meta-analysis, one located in ACCN1 gene also showed
weak association (P = 0.0056) with venous thrombosis in a sample of 1,946 cases and 1,228 controls.
Conclusions: This study has generated new knowledge on genomic regions deserving further investigations in the
search for genetic factors influencing vWF and FVIII plasma levels, some potentially implicated in VT, as well as
providing some supporting evidence of previously identified genes.
Background
Elevated plasma levels of factor VIII (FVIII) and von
Willebrand factor (vWF), two key molecules of the coa-
gulation cascade, are well-established risk factors for
venous thrombosis (VT) [1-3]. More recent evidence
shows that these plasma hemostatic proteins are also
risk factors for other cardiovascular diseases (CVD)
[4-8]. The broader role of FVIII and vWF is further sup-
ported by studies showing that genetic factors modulat-
ing the variability of these proteins are also associated
with CVD. These include single nucleotide polymorph-
isms (SNPs) at the BAI3 [9], LDLR [5,10], VWF [4] and
ABO [11] genes, the latter being associated with other
quantitative risk factors for CVD [12,13].
The estimated heritability of FVIII and vWF levels
range between 40% and 60% [14,15] among which about
20% is attributable to the ABO locus. A genome wide
association study (GWAS) within the CHARGE consor-
tium [16] has recently identified five new genes, apart
from their structural genes and ABO, consistently influ-
encing vWF and/or FVIII plasma levels. These include
CLEC4M, SCARA5, STX2, STXBP5 and TC2N, collec-
tively explaining ~10% of the variability of each two
traits. These observations suggest that there are addi-
tional genetic factors remaining to be identified and
contributing to the hidden heritability of these quantita-
tive traits.
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been recognized in family-based studies but more
recently the putative advantages of carefully selected
samples for quantitative trait analysis of unrelated sub-
jects has also been highlighted [17]. Therefore, we
undertook the combined analysis of individual data from
three GWAS performed in samples of VT patients and
in extended families ascertained on VT and Factor V
Leiden (FVL) to identify novel genetic factors implicated
in the variation of plasma levels of FVIII and vWF.
Methods
Overall strategy
To achieve our primary goal of identifying new genetic
factors that could influence vWF and/or FVIII plasma
levels, we used data from three carefully selected inde-
pendent GWAS. Great attention was drawn to the
homogeneity across samples in terms of - ethnic back-
ground (most individuals were of French origin), -
exclusion criteria with respect to rare forms of inherited
thrombophilia, - objectively diagnosed VT, - studied
intermediate phenotypes (although some adjustments
were done) and similar genotyping technologies (Illu-
mina platform).
In the context of quantitative trait GWAS, individual
genetic effect sizes are known to be small [18] and it is
expected that a number of real associations do not
reach genome-wide significance. Therefore, as part of
our analytic strategy, we first tested for association in
the individual studies, and results observed across sam-
ples were combined into a meta-analysis. We then
focused on the consistency of associations across studies
as our hypothesis was that real associations would more
likely be consistently observed across studies given that
each study samples were quite homogeneous with
respect to the above-mentioned characteristics. Pre-
viously reported associations were also investigated
using the above strategy.
As genetic variants associated to plasma levels of FVIII
and vWF could be risk factors for VT, our secondary
goal was to test the identified SNPs with VT using an in
silico GWAS [19]. Analytic approaches and samples
characteristics of the FVIII and vWF GWAS are
described below.
FVL-families sample
Five extended French-Canadian families were ascer-
tained through single probands with idiopathic VT diag-
nosed at the Thrombosis Clinic of the Ottawa Hospital,
and carrying the FVL mutation. VT cases secondary to
cancer as well as rare forms of inherited VT (protein S,
protein C, AntiThrombin deficiencies) were excluded. A
pedigree was drawn from interviews with each potential
probands. The largest families were invited to participate
in the study - the family size and willingness to partici-
pate being the only criteria for the selection of the
families (see Additional File 1, File S1 for the used ques-
tionnaire). The total number of family members was
255. Description of the extended families has been pub-
lished elsewhere [9].
MARTHA samples
The MARseille THrombosis Association (MARTHA)
project is composed of two independent samples of VT
patients, named MARTHA08 (N = 1,006) and
MARTHA10 (N = 586). MARTHA subjects are unre-
lated caucasians consecutivel yr e c r u i t e da tt h eT h r o m -
bophilia center of La Timone hospital (Marseille,
France) between January 1994 and October 2005. All
patients had a documented history of VT and free of
well characterized genetic risk factors including AT, PC,
or PS deficiency, homozygosity for FV Leiden or FII
20210A, and lupus anticoagulant. They were interviewed
by a physician on their medical history, which empha-
sized manifestations of deep vein thrombosis and pul-
monary embolism using a standardized questionnaire
(see Additional file 2, File S2). The thrombotic events
were confirmed by venography, Doppler ultrasound,
spiral computed tomographic scanning angiography,
and/or ventilation/perfusion lung scan. All the subjects
were of European origin, with the majority being of
French descent.
The main characteristics of the three samples are
shown in Table 1.
In silico GWAS study on VT
In a previously published GWAS on VT [19], 419 early
age of onset and the idiopathic character of VT (ie with-
out environemental risk factors) (< 50 years) VT cases
were compared to 1,228 healthy controls at 291,872
Table 1 Main Characteristics of the Studied Samples
FVL Families
N = 253
MARTHA08
N = 972
MARTHA10
N = 570
Age (SD) 40.4 (17.9) 45.7 (14.9) 49.2 (15.7)
Sex (% female) 50.6% 70.8% 58.2%
Smoking (%) 24.4% 24.9% 22.71%
History of VT (%) 5.95% 100% 100%
PT G20210A carriers 0.40% 15.9% 10.6%
FV Leiden carriers 24.9% 26.6% 14.1%
ABO blood group (%)
O 40.6% 22.9% 22.4%
A 57.8% 61.8% 59.3%
B 1.6% 10.3% 14.4%
AB - 5% 3.9%
FVIII (SD) IU/dL 118.6 (38.51) 138.70 (55.34) 130.2 (46.35)
vWF (SD) IU/dL 130.3 (53.24) 152.33 (68.23) 152.9 (63.93)
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medical centers (Grenoble, Marseille, Montpellier, Paris)
selected according to the same criteria as the MARTHA
samples, except with the restriction on age of onset.
Controls were French subjects selected from the SUVI-
MAX population [20].
Measurements
In the French-Canadian (FVL) sample, plasma levels of
FVIII activity were measured by a clotting assay on the
BCS instrument (Siemens Diagnostics, Marburg Ger-
many) and vWF antigen was measured with a commer-
cially available ELISA kit from Diagnostica Stago. The
interassay coefficients of variation for FVIII were ~ 1%
and 6.1% for vWF.
In MARTHA subjects, plasma coagulant activity and
vWF antigen were assayed in an automated coagul-
ometer (STA-R; Diagnostica Stago, Asnières, France).
The interassay coefficients of variation for FVIII and
vWF were 6.96% and 2.27% respectively.
Genotyping
The French-Canadian sample was genotyped with the
Illumina 660W-Quad Beadchip. The raw datafile con-
tained data for 547,886 autosomal SNPs genotyped on
255 individuals. From these SNPs, 490,083 passed the
quality control (QC) criteria of genotyping rate > 90%
and more than 20 observations of the minor allele
among all individuals. After removing the 88,390 SNPs
that failed QC, the overall genotyping rate was 99.88%.
The maximum missing rate per sample for all the 255
samples was 3.9%, with an average missing rate of
0.13%. The family structures had previously been
checked using 1079 microsatellite markers and
RELPAIR [9]. To further verify the correctness of the
family structure, we used PREST [21] and computed
IBD estimates for all the sample pairs, within and across
pedigrees. PREST reported 14,949 Mendelian errors,
which is equivalent to a very low Mendelian error rate
of 0.012% among all genotypes. Genotypes showing
Mendelian inconsistencies were excluded from the ana-
lysis. Finally, phenotypic and genotypic data were avail-
able on a total of 253 individuals.
The MARTHA08 study sample was typed in 2008
with the Illumina Human610-Quad Beadchip containing
567,589 autosomal SNPs while the MARTHA10 sample
was recently typed (beginning of 2010) with the same
Illumina Human660W-Quad Beadchip as in the FVL
study sample. SNPs showing significant (P < 10
-5) devia-
tion from Hardy-Weinberg equilibrium, with minor
allele frequency (MAF) less than 1% or genotyping call
rate < 99%, in each study were filtered out. Individuals
with genotyping success rates less than 95% were
excluded from the analyses, as well as individuals
demonstrating close relatedness as detected by pairwise
clustering of identity by state distances (IBS) and multi-
dimensional scaling (MDS) implemented in PLINK soft-
ware [22]. Non-European ancestry was also investigated
using the Eigenstrat program [23] leading to the final
selection of 972 and 570 patients left for analysis in
MARTHA08 and MARTH10, respectively. Plasma vWF
levels were available in 834 and 537 MARTHA08 and
MARTHA10 patients, respectively; corresponding num-
bers were 541 and 548 for plasma FVIII levels. A total
of 442,728 SNPs were common to the three GWAS
datasets (see Additional file 3, Figure S1).
Statistical analysis
In the FVL families, association of SNPs with vWF and
FVIII levels was tested by means of measured genotype
linear association analysis as implemented in the
SOLAR (version 4.0, http://solar.txbiomedgenetics.org/
download.html) program. In MARTHA subjects, asso-
ciation was tested using linear model as implemented in
the PLINK program [22].
In order to handle differences in phenotype distribu-
tions across studies (Figure 1), and any possible devia-
tion from normality, plasma levels of vWF and FVIII
were first normalized before any statistical analysis using
the normal quantile transformation [24], separately in
the French-Canadian sample, MARTHA08 and
MARTHA10. This transformation assigns to each
observed measurement the quantile value of the stan-
dard normal distribution that corresponds to the rank of
this measurement in the original untransformed distri-
bution. Transformed variables are then normally distrib-
uted making linear models applicable, and linear
regression coefficients comparable across studies. Asso-
ciation analyses were then carried out on the trans-
formed variables assuming additive allele effects (0,1, 2
coding according to the number of minor alleles), and
adjusting for age, sex and ABO blood group as tagged
by the ABO rs8176746, rs8176704 and rs505922 [19].
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Figure 1 Box Plot Distribution of FVIII (left) and vWF (right)
Plasma Levels in the Three GWAS Datasets.
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Page 3 of 11When appropriate, haplotype association analyses were
carried out in MARTHA samples using THESIAS soft-
ware [25] to handle the correlation between SNPs, that
is linkage disequilibrium (LD). This widely used software
implements a stochastic-EM algorithm that simulta-
neously estimates the frequencies and the effect on the
studied phenotype of each inferred haplotype. Haplotype
- phenotype associations are then assessed by means of
likelihood ratio tests.
Results obtained in each GWAS datasets were com-
bined in a meta-analysis using the GWAMA program
[26]http://www.sph.umich.edu/csg/abecasis/metal. Both
fixed-effect and random-effect models- based analyses
were conducted. Regression coefficients characterizing
the minor allele effect of each SNP were then combined
(after having checked that the minor allele was the same
in the different populations) using the inverse-variance
method to provide an overall allelic estimate. All
reported P values were 2-sided.
Results
A total of 442,728 QC-validated SNPs were common to
the three GWAS and were tested through a meta-analy-
sis for association with vWF and FVIII plasma levels.
Quantile-quantile plots did not reveal any inflation from
what was expected under the null hypothesis of no asso-
ciation (Figure 2), and no SNP reached the study-wide
significance level of 1.12 × 10
-7 that corresponds to the
Bonferroni correction for the number of tested SNPs.
Applying the less stringent Sidak correction correspond-
ing to a significant threshold of p = 1.16 × 10
-7 would
not have modified this conclusion. We then further
focused on genetic effects that were consistent across
studies and with combined p-value of less than 10
-5.A s
fixed-effect and random-effect analyses provided similar
results for most of the main associations (Tables 2 &3),
the following discussion is based on results obtained
from the fixed-effect model analysis.
Ten SNPs covering seven different genes (Figure 3 -
Table 2) were associated with plasma vWF levels at p <
10
-5 with no strong evidence for heterogeneity across
GWAS as the lowest Mantel-Haenszel observed p-value,
p = 0.036, for the ANKDR6 rs645764 would not pass
multiple testing correction for testing ten SNPs. The
strongest association was observed for rs379440 (P =
9.82 10
-6) mapping the EPB41L4A gene (Table 2).
Another SNP at this locus was also associated with
vWF, rs13361927 (P = 4.51 10
-6), but its association was
due to its complete LD with rs379440, with pairwise r
2
of 0.78, 0.69 and 0.62 in FVL, MARTHA08 and
MARTHA10, respectively. Other vWF-associated SNPs
included the SAFB2 rs732505 (P =9 . 3 81 0
-6), VPS8
rs4686760 (P =1 . 0 81 0
-6) and the KRT18P24 rs1757948
(P = 7.37 10
-6). The last three SNPs, rs1438993,
rs10745527, rs2579103 (with P~ 6 10
-6), were located at
the 12q21.33 locus with no known mapped gene and
were in nearly complete association. Altogether, the
independent signals derived from the rs4686760,
rs379440, rs1757948, rs10745527 and rs732505
explained up to 5.7% and 3.8% of the variability of
plasma vWF levels in MARTHA08 and MARTHA10,
respectively, and 5.3% in the pooled MARTHA samples.
None of the ten vWF-associated SNPs were associated
with plasma FVIII levels (all p > 0.05). However, six
additional SNPs were specifically associated to FVIII
levels with homogeneous effects (Mantel-Haenszel p-
value > 0.05) across studies (Figure 4 - Table 3). The
strongest effect (P = 2.95 10
-6) was observed for
rs7306642, a non synonymous Pro2039Thr variant
within the STAB2 gene, which was one of the recently
identified genes by the CHARGE consortium. However,
our hit rs7306642 was not in LD with any of the two
STAB2 SNPs recently identified, rs4981022 (r
2 <0 . 0 1i n
the three studies) and rs4981021 that served as a proxy
for rs12229292 (r
2 < 0.07 in the three studies). Other
FVIII-associated SNPs included the rs6708166 (P =1 . 3 0
10
-6 )i nt h ep r o x i m i t yo fLBH, the rs1321761 ~ 300 kb
apart from FAM46A (P =9 . 5 41 0
-6 ) and the intronic
VAV2 rs12344583 (P =7 . 9 21 0
-6 ) (Table 3). Lastly, two
SNPs within the ACCN1 gene, rs1354492 and
rs12941510, were found modulating FVIII plasma levels,
the A allele of the former being associated with
increased FVIII levels (b =+ 0 . 1 6 ,P =2 . 4 21 0
-6) and the
A allele of the latter being associated with decreased
levels (b = -0.17, P =5 . 6 71 0
-6). These two SNPs were
in complete negative LD generating three haplotypes,
the sole carrying the rs1354492-A allele being associated
with highest levels (see Additional file 4, Table S1).
Altogether, these five SNPs (i.e. rs6708166, rs1321761,
rs12344583, rs7306642, rs1354492) explained 8.2% and
Figure 2 Quantile-Quantile Plots of the Association Results
from the Meta-Analysis of the Three GWAS Datasets.
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Page 4 of 114.6% of the variability of FVIII levels in MARTHA08
and MARTHA10, respectively, and 6.3% in the com-
bined MARTHA samples.
We then used our GWAS datasets to investigate SNPs
that had previously been reported associated with vWF
and/or FVIII [4,5,9,16]. As shown in Supplementary
Table two, marginal associations (P < 0.05) with vWF
levels at STXBP5, VWF, STX2, TC2N and CLEC4M
were also observed in our study, the strongest (P = 1.3
10
-4) being for SNP rs216335 at the structural VWF
gene. All these associations were consistent (i.e the
same allele was associated with a genetic effect in the
same direction on the studied phenotype) with those
previously reported. Together, these associations
explained an additional 1.4% and 3.2% of the variance of
plasma levels of vWF in MARTHA08 and MARTHA10,
r e s p e c t i v e l y .W ed i dn o to b s e r v ea n ye v i d e n c ef o ra n
effect of STAB2 rs4981022 or BAI3 rs9363864, while the
effect of SCARA5 rs2726953 was heterogeneous across
the studies. For FVIII levels, we observed marginal asso-
ciations of SCARA5 rs9644133 (P = 0.009) and VWF
rs1063856 (P = 0.020) that were consistent with those
previously reported (Table 4), these two SNPs explaining
0.7% and 0.2% of FVIII variability in MARTHA08 and
MARTHA10, respectively. No trend for association was
observed for the previously reported associations with
STXBP5, STAB2 nor LDLR SNPs (Table 5).
We have recently observed that, among the newly identi-
fied vWF and/or FVIII genes by the CHARGE consortium,
TC2N could also be associated with VT risk [27]. Therefore
Table 2 Ten SNPs Showing Association with vWF levels Across the Three GWAS Datasets With Combined Significance
P-value < 10
-5
Gene SNP Alleles* MAF
+ b (SE) p I
2 phet Random Effect Fixed Effect
b (SE) p b (SE) p
FVL 0.47 -0.16 (0.08) 0.044
VPS8 rs4686760 A/G Martha08 0.46 -0.18 (0.04) 4.11 10
-5 0 0.549 0.15 (0.03) 1.10 10
-6 -0.15 (0.03) 1.08 10
-6
Martha10 0.45 -0.11 (0.05) 0.047
FVL 0.15 0.44 (0.11) 3.08 10
-4
rs13361927 G/A Martha08 0.06 0.28 (0.09) 0.003 0.53 0.119 -0.28 (0.09) 0.002 0.28 (0.06) 4.51 10
-6
EPB41L4A Martha10 0.05 0.11 (0.11) 0.316
FVL 0.12 0.46 (0.12) 8.35 10
-4
rs379440 A/G Martha08 0.04 0.31 (0.11) 0.004 0 0.502 -0.34 (0.07) 9.99 10
-7 0.34 (0.07) 9.82 10
-7
Martha10 0.03 0.25 (0.14) 0.071
FVL 0.04 -0.01 (0.21) 0.977
ANKRD6 rs6454764 C/T Martha08 0.06 0.24 (0.09) 0.007 0.70 0.036 -0.29 (0.14) 0.035 0.31 (0.07) 5.12 10
-6
Martha10 0.05 0.54 (0.12) 8.97 10
-6
FVL 0.27 0.34 (0.09) 2.82 10
-4
KRT18P24 rs1757948 T/G Martha08 0.27 0.1 (0.05) 0.030 0.62 0.071 -0.18 (0.06) 0.003 0.15 (0.03) 7.37 10
-6
Martha10 0.30 0.15 (0.06) 0.009
FVL 0.19 0.15 (0.1) 0.127
rs1438993 G/A Martha08 0.28 0.18 (0.05) 1.11 10
-4 0 0.666 -0.16 (0.03) 6.34 10
-6 0.16 (0.03) 6.25 10
-6
Martha10 0.27 0.12 (0.06) 0.052
FVL 0.20 0.19 (0.1) 0.062
desert rs10745527 T/G Martha08 0.28 0.18 (0.05) 1.63 10
-4 0 0.663 -0.16 (0.03) 5.51 10
-6 0.16 (0.03) 5.43 10
-6
Martha10 0.27 0.11 (0.06) 0.056
FVL 0.18 0.17 (0.11) 0.098
rs2579103 T/G Martha08 0.26 0.19 (0.05) 8.24 10
-5 0 0.533 -0.16 (0.04) 7.72 10
-6 0.16 (0.04) 7.61 10
-6
Martha10 0.25 0.1 (0.06) 0.090
FVL 0.04 -0.02 (0.19) 0.905
CDH2 rs2298574 A/G Martha08 0.08 -0.34 (0.08) 2.77 10
-5 0.19 0.290 0.26 (0.07) 1.81 10
-4 -0.27 (0.06) 5.67 10
-6
Martha10 0.07 -0.24 (0.1) 0.022
FVL 0.05 0.32 (0.18) 0.080
SAFB2 rs732505 G/A Martha08 0.09 0.24 (0.08) 0.001 0 0.929 -0.25 (0.06) 9.50 10
-6 0.25 (0.06) 9.38 10
-6
Martha10 0.08 0.25 (0.1) 0.013
*Common/rare alleles
+ Allele frequency of the minor allele
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meta-analysis on the risk of VT. Our working hypothesis
was that SNPs associated with increased (decreased, resp.)
plasma levels of these two molecules could be associated
with increased (decreased, resp.) risk of disease. For this, we
used the results of our previously published GWAS based
on 419 VT patients and 1228 healthy subjects (in silico
association) [19]. As indicated in Table 6, only two SNPs,
VPS8 rs4686760 and ACCN1 rs12941510, showed some
trend of association consistent with our hypothesis. The
rs4686760-G allele found associated with decreased vWF
l e v e l sw a ss l i g h t l yl e s sf r e q u e n ti nV Tp a t i e n t st h a ni nc o n -
trols (0.441 vs 0.475, P = 0.101) and the rs12941510-A
allele, associated with decreased FVIII levels, was also less
frequent in cases than in controls (0.310 vs 0.350, P =
0.046). These associations cano n l yb ec o n s i d e r e da ss u g g e s -
tive as they would not pass correction for multiple testing.
Nevertheless, the observed homogeneity of the allele fre-
quencies of these two SNPs across all genotyped patients is
noteworthy. Combining all the VT patients (n = 1946), and
comparing to the healthy controls of the in silico GWAS,
the association of rs4686760 with VT remained (0.454 vs
0.475, P = 0.108), and that of rs12941510 was strengthened
(0.314 vs 0.348, P = 0.0056) (Table 7).
Discussion
Theoretically, a sample size of 1,624 unrelated indivi-
duals should have a power of 95% to detect, at the
significant level of 1.12 10
-7, the additive allele effect of
a SNP explaining at least 3% if the variability of a quan-
titative trait [28]. This power would decrease to 86%
and 66% for a SNP explaining 2.5% and 2%, respectively.
Our meta-analysis of 1,624 carefully selected samples
did not reveal any genome-wide significant association
suggesting that the additional common SNPs tagged by
current GWAS array and influencing vWF and FVIII
plasma levels left to be identified would, if any, individu-
ally explain less than 2% of the variability of these two
traits.
By lowering the statistical stringency to p < 10
-5 but
focusing on the homogeneity of the effects observed in
three independent samples, we identified several novel
candidate genes that could contribute to modulate the
variability of vWF and FVIII, and that deserve to be
further studied. The novel candidate genes for vWF are
VPS8, EBP41L4A, KRT18P24, SAFB2 and a region on
12q21.3 where no known gene maps. Unfortunately, lit-
tle is known about the biology of the associated proteins
and their role in cardiovascular diseases. Among these,
VPS8 stands out. The rs4686760-G allele of the VPS8
gene, which was associated with decreased vWF levels,
was also observed less frequently in VT cases than in
healthy controls (0.45 vs 0.48) in the in silico GWAS,
although this observation did not reach significance (P =
0.10). The vacuolar protein sorting 8 homolog gene
(VPS8) is involved in protein traffic between the golgic
Table 3 Six SNPs Showing Association with FVIII Activity Across the Three GWAS Datasets With Combined Significance
P-value < 10
-5
Gene SNP Alleles* MAF
+ b (SE) p I
2 phet Random Effect Fixed Effect
b (SE) p b (SE) p
FVL 0.41 -0.12 (0.09) 0.156
LBH rs6708166 G/A Martha08 0.40 -0.23 (0.06) 8.98e-05 0 0.478 -0.17 (0.04) 1.32 10
-6 -0.17 (0.04) 1.30 10
-6
Martha10 0.42 -0.15 (0.05) 0.007
FVL 0.42 -0.20 (0.08) 0.014
FAM46A rs1321761 T/C Martha08 0.45 -0.10 (0.06) 0.074 0 0.451 -0.15 (0.04) 9.67 10
-6 -0.15 (0.04) 9.54 10
-6
Martha10 0.47 -0.19 (0.05) 5.93e-04
FVL 0.17 0.28 (0.11) 0.012
VAV2 rs12344583 A/G Martha08 0.20 0.19 (0.07) 0.006 0 0.716 0.20 (0.04) 8.03 10
-6 0.20 (0.04) 7.92 10
-6
Martha10 0.18 0.17 (0.07) 0.012
FVL 0.16 0.52 (0.12) 1.36e-05
STAB2 rs7306642 C/A Martha08 0.07 0.22 (0.11) 0.057 0.59 0.086 0.31 (0.10) 0.002 0.30 (0.06) 2.95 10
-6
Martha10 0.07 0.20 (0.1) 0.052
FVL 0.53 0.09 (0.08) 0.293
rs1354492 G/A Martha08 0.49 0.23 (0.05) 1.20e-05 0.39 0.192 0.16 (0.04) 5.47 10
-6 0.16 (0.03) 2.41 10
-6
ACCN1 Martha10 0.47 0.12 (0.05) 0.027
FVL 0.22 -0.29 (0.1) 0.004
rs12941510 G/A Martha08 0.31 -0.17 (0.06) 0.002 0.12 0.321 -0.17 (0.04) 2.18 10
-5 -0.17 (0.04) 5.67 10
-6
Martha10 0.33 -0.12 (0.06) 0.029
*Common/rare alleles
+ Allele frequency of the minor allele
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Page 6 of 11appartus and the vacuaole [29] and could participate to
the regulation of urokinase-type plasminogen activator
[30], the latter known to be involved in thrombosis.
For FVIII levels, the candidate genes identified in our
study were LBH, FAM46A, VAV2, STAB2 and ACCN1.
Both LBH and VAV2 genes are thought to be involved
in angiogenesis. The transcriptional cofactor limb-bud-
and-heart (Lbh) was discovered as a small acidic nuclear
protein highly conserved among species [31]. It has
been demonstrated a dramatic suppression of VEGF
mRNAs in cells that overexpress Lbh [32]. Vav2 is a
g u a n i n en u c l e o t i d ee x c h a n g ef a c t o rf o rR h of a m i l yp r o -
teins. The expression of a dominant negative form of
Vav2 suppress the Vascular Endothelial-Protein Tyro-
sine Phosphatise (VE-PTP)-induced changes in endothe-
lial cell morphology, such changes being implicated in
regulation of angiogenesis [33].
Interestingly, we had previously shown that STAB2
was located within a linkage peak for vWF levels in
our FVL extended families [9] while almost
concomitantly STAB2 SNPs were found associated
with both FVIII and vWF in the CHARGE consortium
GWAS [16]. However, the non-synonymous rs7306642
(Pro2039Thr) found associated here with FVIII levels
did not show a homogeneous effect on vWF levels
across the three GWAS datasets (data not shown), and
was in very low LD with others STAB2 SNPs found
associated with these plasma levels. The substitution of
a Proline by a Threonine at position 2039 is predicted
to be damaging according to web resources http://
genetics.bwh.harvard.edu/pph/index.html; http://www.
rostlab.org/services/SNAP. Investigating the effect of
this substitution on VT risk would have been relevant
but the corresponding SNP did not pass quality con-
trol in our in silico GWAS. These observations never-
theless suggest that an in-depth haplotype analysis of
the STAB2 gene are required to gain better insight
into which SNPs more likely influence plasma levels of
FVIII and/or vWF.
ACCN1, encoding an amiloride-sensitive cation chan-
nel implicated in cell growth and migration [34], is
another gene that deserves greater attention as its
genetic variability was found here associated with both
FVIII levels and VT risk. However, the SNP that seemed
to modulate FVIII levels the most, rs1354492, was not
the one that showed association with the disease. This
could suggest that either different SNPs distinctly influ-
ence plasma levels and VT risk, or that the identified
SNPs are in LD with unmeasured variant(s) that could
simultaneously influence both phenotypes.
$OOHOH (IIHFW

Figure 3 Forest plot representation of the ten SNPs that
associated the most with vWF levels in the Three GWAS
Datasets. Results observed in the FVL families, MARTHA08 and
MARTHA10 studies are depicted by square, circle and triangle,
respectively.
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
Figure 4 Forest plot representation of the six SNPs that
associated the most with FVIII levels in the Three GWAS
Datasets. Results observed in the FVL families, MARTHA08 and
MARTHA10 studies are depicted by square, circle and triangle,
respectively.
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the previously reported associations between SNPs and
vWF/FVIII levels. Replicated associations include vWF-
associated SNPs at STXBP5, VWF, STX2, TC2N and
CLEC4M genes, and FVIII-associated SNPs within
SCARA5 and VWF genes. Other previously reported
associations were not replicated, such as those involving
LDLR, BAI3,a n dSTAB2 SNPs [5,9,16]. In addition to a
lack of power, as previously discussed, this could be due
to differential effects of SNP in normal range of plasma
levels compared to the higher levels observed in VT
patients. This could apply to the association of BAI3
with vWF levels observed in healthy nuclear families [9]
where plasma levels were lower than those observed in
our VT samples. Conversely, this explanation does not
completely hold for the LDLR SNPs that were found
associated with FVIII activity in a population [5] where
FVIII activity in healthy individuals were at higher levels
than those observed in our VT patients. Besides, in
these two studies, different methods from those we have
used here were employed to measure vWF and FVIII
activity, and this could also contribute to the discrepan-
cies observed in our study.
Conclusions
In conclusion, a carefully planned meta-analysis of three
independent samples gathering 1,624 individuals geno-
typed for more than 400,000 SNPs all over the genome
Table 4 Association of Previously Identified SNPs with vWF Levels in the three GWAS Datasets
Gene SNP Alleles* MAF
+ b (SE) p I
2 phet Random Effect Fixed Effect
b (SE) p b (SE) p
FVL 0.42 0.04 (0.08) 0.618
BAI3 rs9363864 A/G Martha08 0.52 0.03 (0.04) 0.421 0 0.838 0.02 (0.03) 0.461 0.02 (0.03) 0.461
Martha10 0.49 -0.002 (0.05) 0.973
FVL 0.43 -0.08 (0.08) 0.366
STXBP5 rs9390459 G/A Martha08 0.42 -0.06 (0.04) 0.197 0 0.545 -0.09 (0.03) 0.005 -0.09 (0.03) 0.005
Martha10 0.43 -0.13 (0.05) 0.011
FVL 0.20 -0.08 (0.10) 0.446
SCARA5 rs10866867
(1) G/T Martha08 0.25 0.17 (0.05) 4.88e-04 0.71 0.03 0.05 (0.07) 0.466 0.09 (0.04) 0.015
Martha10 0.25 0.01 (0.06) 0.830
FVL 0.06 -0.28 (0.19) 0.141
rs216335
(2) G/A Martha08 0.08 -0.23 (0.08) 0.003 0 0.945 -0.23 (0.06) 1.31 10
-4 -0.23 (0.06) 1.30 10
-4
Martha10 0.06 -0.21 (0.11) 0.059
FVL 0.45 0.07 (0.08) 0.371
VWF rs1063856
(3) A/G Martha08 0.37 0.08 (0.05) 0.094 0 0.889 0.09 (0.03) 0.006 0.09 (0.03) 0.006
Martha10 0.38 0.11 (0.05) 0.041
FVL 0.48 -0.04 (0.08) 0.612
rs7306706 A/G Martha08 0.45 0.02 (0.04) 0.634 0 0.754 0.01 (0.03) 0.664 0.01 (0.03) 0.664
Martha10 0.46 0.03 (0.05) 0.604
FVL 0.30 -0.05 (0.09) 0.601
STAB2 rs4981022 T/C Martha08 0.30 0.02 (0.05) 0.652 0 0.541 -0.01 (0.03) 0.664 -0.01 (0.03) 0.664
Martha10 0.28 -0.06 (0.06) 0.333
FVL 0.33 0.01 (0.09) 0.863
STX2 rs4334059
(4) C/T Martha08 0.37 0.08 (0.04) 0.067 0.01 0.363 0.1 (0.03) 0.004 0.1 (0.03) 0.003
Martha10 0.36 0.15 (0.06) 0.008
FVL 0.52 0.05 (0.08) 0.548
TC2N rs2402074
(5) G/A Martha08 0.48 0.04 (0.04) 0.382 0 0.509 0.07 (0.03) 0.033 0.07 (0.03) 0.033
Martha10 0.47 0.12 (0.05) 0.030
FVL 0.22 -0.07 (0.1) 0.515
CLEC4M rs868875 A/G Martha08 0.32 -0.10 (0.05) 0.036 0 0.762 -0.08 (0.03) 0.026 -0.08 (0.03) 0.026
Martha10 0.35 -0.05 (0.06) 0.424
* Common/rare alleles
+ Allele frequency of the minor allele
(1) rs10866867 serves as proxy for rs2726953 (r
2 = 0.92);
(2) rs216335 serves as proxy for rs216318 (r
2 =1 )
(3) rs1063856 serves as proxy for Rs1063857 (r
2 = 1);
(4) rs4334059 serves as proxy for rs7978987 (r
2 = 1.0
(5) rs2402074 serves as proxy for rs10133762 (r
2 = 0.96); No good proxy with r
2 > 0.5 was available for the VWF rs4764478
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Page 8 of 11Table 5 Association of Previously Identified SNPs with FVIII Activity in the three GWAS Datasets
Gene SNP Alleles* MAF
+ b (SE) p I
2 phet Random Effect Fixed Effect
b (SE) p b (SE) p
FVL 0.43 0.15 (0.08) 0.083
STXBP5 rs9390459 G/A Martha08 0.42 -0.08 (0.06) 0.158 0.65 0.059 -0.02 (0.06) 0.795 -0.04 (0.03) 0.310
Martha10 0.43 -0.07 (0.05) 0.199
FVL 0.24 -0.08 (0.1) 0.433
SCARA5 rs9644133 C/T Martha08 0.17 -0.16 (0.07) 0.029 0 0.753 -0.12 (0.05) 0.009 -0.12 (0.05) 0.009
Martha10 0.18 -0.10 (0.07) 0.152
FVL 0.45 0.11 (0.08) 0.170
VWF rs1063856 A/G Martha08 0.37 0.09 (0.06) 0.114 0 0.843 0.08 (0.03) 0.020 0.08 (0.03) 0.020
Martha10 0.38 0.06 (0.05) 0.249
FVL 0.27 -0.13 (0.09) 0.146
STAB2 rs4981021
(1) G/A Martha08 0.32 -0.02 (0.06) 0.737 0 0.389 -0.02 (0.04) 0.521 -0.02 (0.04) 0.521
Martha10 0.29 0.02 (0.06) 0.782
FVL 0.14 -0.03 (0.11) 0.816
rs2228671 C/T Martha08 0.11 0.11 (0.09) 0.193 0.46 0.157 -0.01 (0.07) 0.890 -0.01 (0.05) 0.894
LDLR Martha10 0.10 -0.13 (0.09) 0.161
FVL 0.38 -0.25 (0.09) 0.005
rs688 C/T Martha08 0.45 0.06 (0.05) 0.235 0.79 0.010 -0.05 (0.08) 0.531 -0.02 (0.03) 0.652
Martha10 0.45 -0.007 (0.05) 0.901
* Common/rare alleles
+ Allele frequency of the minor allele
(1) rs4981021 serves as proxy for rs12229292 (r
2 = 0.88)
Table 6 In Silico Association With Venous Thrombosis of the Identified vWF- and FVIII Associated SNPs
Alleles* Minor Allele Frequency Cochran Armitage P-value
Cases Controls
vWF associated SNPs
VPS8 rs4686760 A/G 0.441 0.475 P = 0.101
EPB41L4A rs13361927 G/A 0.065 0.062 P = 0.797
KRT18P24 rs1634352† G/A 0.284 0.318 P = 0.055
12q21.33 rs1438933 G/A 0.256 0.294 P = 0.051
CDH2 rs2298574 A/G 0.084 0.093 P = 0.444
SAFB2 rs732505 G/A 0.061 0.064 P = 0.713
FVIII associated SNPs
VAV2 rs12344583 A/G 0.217 0.193 P = 0.133
ACCN1 rs1354492 G/A 0.476 0.469 P = 0.740
ACCN1 rs12941510 G/A 0.310 0.350 P = 0.046
*Common/minor alleles
† serves as proxy for rs1757948 (r
2 = 1).
No good proxy with r
2 > 0.80 was available for rs6708166 (LBH), rs1321761 (FAM46A) and rs7306642 (STAB2)
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Page 9 of 11replicated very recent findings but did not reveal any
new genetic factors that could individually explain at
least 2% of the plasma variability of vWF and FVIII
levels.
Additional material
Additional file 1: FVL Family Questionnaire.
Additional file 2: MARTHA questionnaire. Excel file illustrating the
questionnaire used for selecting MARTHA VT patients.
Additional file 3: Figure S1. Genotype filtering strategy applied to
the three GWAS datasets.
(1) A genotype calling rate of > 0.90 was
used in the FVL families and a threshold of 0.99 was used for the
MARTHA patients.
(2) SNPs with minor allele frequency less than 0.04 and
0.01 in FVL families and MARTHA patients, respectively, were excluded
from the analysis.
(3) SNPs demonstrating deviation from Hardy-Weinberg
equilibrium at p < 10
-5 were excluded. 217 SNPs failed the genotype
calling criterion simultaneously in the three study samples and this
number was 19,111 for the minor allele frequency criterion. 19 SNPs
failed the Hardy-Weinberg criterion in MARTHA08 and MARTHA10.
Additional file 4: Table S1. Haplotype Association Analysis of ACCN1
rs1354492 and rs12941510 With Plasma FVIII levels in MARTHA08
and MARTHA10 Studies.
(1) Haplotypic effect associated with each
haplotype by comparison to the most frequent AG haplotype under the
assumption of haplotype additive effects. Analyses were adjusted for age,
sex and ABO blood group.
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